Andere Sprachen Altamira Therapeutics Ltd.

Aktien

A2PJN3

BMG0360L1349

CYTO

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:43:35 26.06.2024			% 5 Tage	% 1. Jan.
1.085 ^USD	-1.36%		-12.00%	-68.39%

20.06.	Altamira Therapeutics Ltd. hebt neu veröffentlichten Übersichtsartikel hervor, der die Verwendung von Betahistin bei der Behandlung von Schwindel unterstützt	CI
16.05.	Altamira Therapeutics Ltd. wählt Dominik Lysek als Mitglied des Verwaltungsrats	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management	20.06.
Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management	20.06.
Altamira Therapeutics Provides Business Update	28.05.
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal	23.05.
Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors	16.05.
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01.05.
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01.05.
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24.04.
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24.04.
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	16.04.
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	10.04.
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	10.04.
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	04.04.
Sector Update: Health Care Stocks Decline Late Afternoon	25.03.
Top Midday Gainers	25.03.
Sector Update: Health Care Stocks Softer in Afternoon Trading	25.03.
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	25.03.
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25.03.
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25.03.
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Altamira Therapeutics Ltd.

Aktien

A2PJN3

BMG0360L1349

CYTO

Andere Sprachen

Filter